O
Oncohost
Develops personalized strategies to maximize the success of cancer therapy
About Oncohost
OncoHost is a pioneering startup in the field of precision oncology, operating in the biotechnology market. The company's primary offering is the PROphet® platform, a cutting-edge technology that integrates bioinformatics, system biology, proteomic pattern recognition, and machine learning. This platform is designed to predict the clinical benefits of PD-1/PD-L1 inhibitors, a type of cancer therapy, and provide evidence-based treatment considerations. In simpler terms, it uses complex algorithms to analyze the interaction between the patient, the tumor, and the therapy, and predicts how well the patient will respond to the treatment.
Read full description
The company's clients are primarily healthcare providers and oncology specialists who are looking for more precise and effective treatment strategies for their patients. By providing early prediction of clinical benefits from PD-1/PD-L1 inhibitors, OncoHost's platform can help doctors make more informed decisions about the best course of treatment for their patients.
OncoHost operates on a B2B business model, generating revenue by selling access to its PROphet® platform to healthcare providers and medical institutions. The company's innovative approach to precision oncology has been recognized in the industry, with OncoHost being named the Best Precision Oncology Solutions Developer in the Middle East at the Biotechnology Awards 2023.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Hadera, Israel
- Employees
- 44
- Open positions
- None listed
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Tech for Hospitals and Clinics, Clinical Decision Support, Biotech and Pharma, Horizon Europe, proteomics, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Oncohost.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | May 2022 | $35M | $140M | OurCrowd · Menora Mivtachim · Leumi Partners · ALIVE Israel HealthTech Fund | ↗ |
| SERIES B✓Equity / VC | Jan 2021 | $8M | $32M | OurCrowd | — |
Growth signals
Latest recorded traffic for Oncohost is 2.6K monthly website visits, up 0% over the last three months. Oncohost's team declined 10.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Om Maya
BIRD Foundation
Series A1 investor entered at this stage
Series B and later3 investors entered at this stage
ALIVE Israel HealthTech Fund- MMMenora Mivtachim
Leumi Partners
Other known investors3 additional known investors
Technion Israel Institute of Technology- DKDudi Klein
European Innovation Council
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oncohost on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oncohost’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.